The first batch doses of the AstraZeneca vaccine against the new coronavirus, as the Japanese subsidiary of the company informed Asahi Shimbun.
The company originally intended to import insoluble quantities of the product from the European Union, but Brussels imposed stricter restrictions on vaccine exports about the new coronavirus at the end of January, as an executive of the Japanese subsidiary of the Anglo-Swedish company responsible for vaccines explained in an interview published today in the newspaper.
A representative of AstraZeneca confirmed that this is now the company’s plan, as broadcast by AMPE.
Gradually, the vaccine will begin to be produced on its own Japan, after approval by the Japanese regulators, something that is expected to happen in May.
The CEO of AstraZeneca’s Japanese subsidiary, Tomu Tanaka, did not specify how many doses are currently available in Japan.
Daiichi Sankyo Co announced last month that started production of the AstraZeneca vaccine domestically.
The Japanese government intends to buy 120 million doses, enough to vaccinate 60 million people. About 90 million doses will be produced domestically by Daiichi Sankyo, JCR Pharmaceuticals and other partners.
The EU has decided to limit exports of vaccines produced in its Member States to ensure the availability of installments.
Although the AstraZeneca vaccine has not yet received an emergency use permit in the US, the US government intends to keep some of the doses produced in its territory so that they can be disposed of as soon as the approval of the Federal Drug Administration (FDA).
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
